Comparative Pharmacology
Head-to-head clinical analysis: ALDURAZYME versus NAGLAZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDURAZYME versus NAGLAZYME.
ALDURAZYME vs NAGLAZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALDURAZYME (laronidase) is a recombinant form of human α-L-iduronidase, an enzyme that hydrolyzes terminal α-L-iduronic acid residues in glycosaminoglycans (GAGs) such as dermatan sulfate and heparan sulfate. It replaces the deficient enzyme in patients with mucopolysaccharidosis I (MPS I), reducing lysosomal accumulation of GAGs.
NAGLAZYME (galsulfase) is a recombinant form of human N-acetylgalactosamine 4-sulfatase that replaces deficient endogenous enzyme in patients with mucopolysaccharidosis VI (MPS VI). It catalyzes the hydrolysis of N-acetylgalactosamine 4-sulfate groups from glycosaminoglycans (GAGs), reducing GAG accumulation in lysosomes.
0.58 mg/kg administered intravenously once weekly.
1 mg/kg intravenously once weekly.
None Documented
None Documented
Terminal half-life: 6–10 minutes (rapid clearance from plasma due to cellular uptake via mannose-6-phosphate receptors); clinical context: clearance is saturable, leading to longer effective half-life at therapeutic doses
Terminal elimination half-life: 6-9 minutes (0.1-0.15 hours); clinically, rapid clearance requires weekly intravenous administration to maintain therapeutic levels.
Renal: negligible; primarily catabolism via peptide hydrolysis; no significant biliary/fecal elimination
Renal: 87% of administered dose excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy